Live coverage has ended. The full story is below.
The S&P 500 experienced one of the worst stretches in the index’s history driven mainly by President Trump’s escalation of tariffs on China. The market has fallen 17.5% since its high in mid-February but the two day drop starting last Friday through the market close yesterday was the 5th worst stretch in the past 80 years.
Tuesday brings some signs of recovery. The S&P 500 rose 3.09% to 5218.73 shortly after the open, joined by a 3.41% gain in the Nasdaq and 3.02% in the Dow. Treasury Secretary Scott Bessent’s comments about potential “good deals” with Japan and other nations fueled optimism, lifting Japan’s Nikkei 225 by 6%. China, however, remains defiant, pledging to “fight to the end” while weakening the yuan, hinting at a prolonged trade conflict despite President Trump saying “China wants to make a deal, badly” in a Truth Social post.
Stocks on the move
Health insurance stocks are S&P 500’s biggest winners today following a significant boost to Medicare reimbursement rates.
Humana (
NYSE: HUM |
HUM Price Prediction) and
UnitedHealth (
NYSE:UNH) are up 12.78% and 7.45% respectively, after the Center for Medicare & Medicaid Services finalized a 5.06% average increase in 2026 Medicare Advantage payments, more than double the expected increase.
Eli Lilly (
NYSE: LLY) shares are gaining 5.06% today following a significant upgrade from Goldman Sachs. The firm raised its rating on the pharmaceutical giant to Buy from Neutral, setting a price target of $888. Analyst notes highlight a “compelling entry point” into what they call the “sector’s premier topline grower” after a recent sell-off. With its strong portfolio, including drugs like Mounjaro and Zepbound, the company is poised to maintain its “pole position” in this rapidly expanding space, driving investor optimism.
Johnson & Johnson (
NYSE: JNJ) is up 1.5%, also after Goldman Sachs’ Buy rating and a $172 price target. The firm argues that market concerns over the looming Stelara loss of exclusivity are overstated. In a research note, the analyst points out that consensus estimates fail to fully capture the strength of J&J’s Innovative Medicine business. As the company moves past the Stelara patent cliff, it’s entering a phase of robust new product cycles across multiple high-potential markets. This optimistic outlook underscores J&J’s resilience and growth potential, boosting confidence among investors.
Contact [email protected] for any questions or corrections.